Eciskafusp Alfa + Atezolizumab for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called eciskafusp alfa alone and with atezolizumab in adults with certain types of cancer. These drugs help the immune system attack cancer cells. Atezolizumab is an approved treatment for various cancers, including bladder cancer and lung cancer.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Atezolizumab in treating cancer?
Atezolizumab has shown effectiveness in treating various cancers, including urothelial carcinoma and non-small cell lung cancer, by improving overall survival rates in clinical trials. It has also been approved for use in metastatic triple-negative breast cancer, demonstrating promising results in international Phase III trials.12345
Is the combination of Eciskafusp Alfa and Atezolizumab safe for humans?
Atezolizumab, also known as Tecentriq, has been studied in various cancers and generally has an acceptable safety profile. Common side effects include tiredness, loss of appetite, and nausea, while more serious effects can include lung inflammation, liver inflammation, and thyroid issues. However, specific safety data for the combination with Eciskafusp Alfa is not provided in the available research.12356
What makes the drug Atezolizumab unique for cancer treatment?
Atezolizumab is unique because it is a monoclonal antibody that targets PD-L1, a protein that helps cancer cells evade the immune system, thereby enhancing the body's immune response against tumors. It has shown promising results in various cancers, including lung and breast cancer, by improving overall survival rates compared to traditional chemotherapy.12357
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for adults with advanced solid tumors that have no standard treatments available or can't tolerate them. Participants should have a life expectancy of at least 12 weeks, measurable disease, and be in relatively good health (able to perform daily activities without significant assistance). They must not have severe allergies to certain antibodies or proteins, untreated brain metastases, other active cancers, certain viral infections like HIV or hepatitis B/C, recent major surgeries or injuries.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose-Escalation (Part 1)
Dose-escalation of eciskafusp alfa as a single agent
Dose-Escalation (Part 2)
Dose-escalation of eciskafusp alfa in combination with atezolizumab
Extension (Part 3)
Extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Atezolizumab
- RO7284755
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University